Key Highlights

  • Bioventix plc (LSE:BVXP) is listed on AIM with a Dividend Yield of 7.41%.
  • The Interim Dividend was held at 70p per share, paid on 24 April 2026.
  • The total dividend for FY25 was 150p per share, including an 80p second interim.
  • H1 Revenue fell 8.5% to £6.2m and pre-tax profit eased 3.9% to £4.9m.
  • Royalties from Tau and neurology antibodies rose five-fold to £150,000.
  • The board is using reserves to maintain the dividend at historic levels.

Overview of Bioventix

Bioventix plc (LSE:BVXP) specialises in high-affinity sheep monoclonal antibodies used in clinical diagnostics, particularly in automated blood tests run by the world's largest diagnostics companies. Its antibodies are used in tests for heart disease, thyroid function, fertility, cancer and more. The company earns royalties when customers sell tests containing its antibodies.

The 7.41% yield reflects a generous policy of distributing most profits, combined with a share price that has drifted as legacy revenues mature.

Latest Results

For the six months ended 31 December 2025, revenue fell 8.5% to £6.2m, or £6.4m on a constant currency basis. Pre-tax profit fell 3.9% to £4.9m. Closing cash was £5.3m. Trading remained in line with expectations for the year to 30 June 2026, with management expecting a modest annual revenue decline. Some of the decline reflected product Maturity and challenging conditions in China.

Dividend Record

Bioventix pays two interim dividends a year. It paid 150p for FY25, comprising a 70p first interim and an 80p second interim, after 155p in FY24 and 152p in FY23. For FY26, the first interim was held at 70p, paid on 24 April 2026. A second interim has historically been paid in November.

Dividend Cover

Cover has been close to 1 times, at 0.97 times in FY25. Management said the resilience of the core products and small operating base allow flexibility to use reserves to maintain the dividend at historic levels. That means the payout currently slightly exceeds profits.

The Alzheimer's Opportunity

Royalties from Tau and neurology antibodies rose five-fold to £150,000, from £30,000, despite relating solely to research-use assays. Among assays being developed by leading diagnostics companies, three use at least one Bioventix antibody. When clinical tests for Alzheimer's are approved, royalties could rise significantly, though timing is hard to predict.

Why Sheep Antibodies Matter

Bioventix's antibodies are generated in sheep and are especially useful where the target is present at low concentration and where conventional antibodies have failed. This technical advantage makes its products hard to replace once designed into a diagnostic test, creating long-lasting Royalty streams. Tests often stay on the market for many years, which explains Bioventix's durable income from mature products such as its vitamin D and troponin antibodies.

Customer Base

Bioventix supplies the majority of multinational clinical diagnostics companies. Among the Alzheimer's research assays being developed, names such as Roche, Siemens, Abbott, Beckman, Quidel-Ortho and Mindray are active in the field. Inclusion in multiple assays increases the chance that at least one approved clinical test will use Bioventix antibodies, potentially generating meaningful royalties for many years.

Research and Development

Modest spending on new antibody development keeps the pipeline refreshed, though higher R&D costs have trimmed profits slightly in recent periods.

Bioventix is debt-free with modest cash. Because it distributes most profits, cash does not build substantially.

Risks

Risks include continued decline of mature products, China market weakness, currency effects and delays in Alzheimer's test approvals. If revenue keeps falling, maintaining 150p may become difficult.

Market Sentiment

Shares rose 5.5% on results day, reflecting optimism about neurology. The price traded around 1,450p to 1,600p in 2026.

How BVXP Fits an Income Portfolio

Bioventix offers a high yield plus a potential growth catalyst from Alzheimer's diagnostics, making it a blend of income and optionality.

Business Model Strength

With a very small team and high margins, Bioventix converts most revenue into profit. This efficiency underpins its ability to pay large dividends relative to its size.

Dividend Sustainability Scorecard

  • Dividend: 70p interim held; 150p annual historically.
  • Cover: slightly below 1 times.
  • Growth: neurology royalties up five-fold.
  • Balance sheet: debt-free.
  • Key risk: mature product decline and approval timing.

What Investors Should Watch

Watch full-year results, the second interim dividend, Alzheimer's test approvals and China trends.

Is the 7.41% Yield Sustainable?

Bioventix's dividend is sustainable short term using reserves, but long-term sustainability depends on neurology royalties replacing declining legacy revenue. LSE:BVXP suits investors seeking income with a diagnostics growth story.